Synthetic lethality is a new method of anti-tumor therapy.PARP inhibitor is the first DNA damage drug designed on this theory,which gives rise to synthetic lethality effect combined with homologous recombi-nation repair deficiency(HRD),and has demonstrated significant efficacy in ovarian cancer and prostate can-cer.The formation of HRD is related to the mutation of BRCA1/2,and the function loss of other homologous recombinant repair proteins.At present,the status of tumor HRD is mainly evaluated by genomic scar analy-sis.In breast cancer,HRD is an important molecular marker,however,the slow progress of related research has limited its clinical application.This comment introduces the formation mechanism,detection methods,re-search progress and difficulties of HRD in breast cancer,to provide new ideas for clinical diagnosis,treat-ment and research design of breast cancer.
维普
万方数据